AMGN decision with link to 245 pg opinion. I think I will skip it. <g>
ij
Friday January 19, 5:30 pm Eastern Time
FACTBOX-Summary of Amgen-Transkaryotic decision
BOSTON, Jan 19 (Reuters) - The following is a summary of a U.S. district court decision in the patent case pitting biotechnology firms Amgen (NasdaqNM:AMGN - news) and Transkaryotic Therapies Inc (NasdaqNM:TKTX - news) over Amgen's blockbuster anti-anemia drug Epogen:
*Claims 1, 2, and 9 of the '933 patent are not infringed, and if this finding is error, those claims are invalid for lack of an adequate written description, indefiniteness, and lack of entablement .
*Claims 4 though 9 of the '698 patent are not infringed.
*Claims 2 through 4 of the '080 are valid, enforceable, and infringed under the doctrine of equivalents.
*Claims 1, 3, 4, and 6 of the '349 patent are valid, enforceable, and literally infringed, whereas Claim 7 of the same patent is not infringed.
*Claim 1 of the '422 patent is valid, enforceable, and literally infringed.
A full copy of the entire decision is available on the web at mad.uscourts.gov. |
